Abstract
Background: The advent of highly active antiretroviral therapy (HAART) has reduced the incidence of most AIDS-related opportunistic illnesses (OI) and death in HIV-infected individuals. We investigated whether there are demographic disparities in H IV disease progression in the HAART era compared with before. Methods: HIV-infected patients in an urban HIV clinical practice in the USA were compared using survival methods for time to a new AIDS-defining OI or death in therapeutic era 1 (monotherapy and combination therapy; 1990-1995; n = 2016) versus era 2 (HAART; 1996-1999; n = 2165). Results: A total of 1037 (51.4%) events occurred in era 1; 666 (30.8%) events occurred in era 2. In women, the median disease-free survival time increased by 14% (CD4 cell counts > 200 cells/mm3 at baseline) and 34% (CD4 cell counts ≤ 200) in era 2 compared with era 1, whereas for men it increased by 43 and 100%. The relative hazard (RH) of progression for women compared with men in era 2 compared with era 1 was 1.34. For injecting drug use (IDU), disease-free survival time increased by 16% and 34% in era 2 compared with era 1, whereas non-IDU improved by 65 and 135%. The RH of progression for IDU compared with non-IDU in era 2 compared with era 1 was 1.39. No significant differences were detected by race or other HIV transmission risk group. Conclusion: Disease-free survival time was extended with the use of HAART, but these gains were not equally distributed by sex and IDU in our cohort.
Original language | English (US) |
---|---|
Pages (from-to) | 1115-1123 |
Number of pages | 9 |
Journal | AIDS |
Volume | 15 |
Issue number | 9 |
DOIs | |
State | Published - Jun 15 2001 |
Keywords
- Antiretroviral therapy
- HIV progression
- Injecting drug use
- Sex
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases